Physician profile
Eric L Putnoi
NPI 1538150487
$11,223.62
in general payments reported to CMS, 2019-2025
29 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $1,160 · 2021: $1,586 · 2022: $1,957 · 2023: $1,859 · 2024: $1,601 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,339.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,364.14 | 2019-2025 | Clareon, Rocklatan, Eysuvis |
| Sun Pharmaceutical Industries INC. | $1,450.12 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $1,133.60 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $1,050.93 | 2022-2025 | |
| Allergan, INC. | $1,027.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $736.76 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $610.94 | 2022-2025 | Vyzulta, Xiidra, Prolensa |
| Kala Pharmaceuticals, INC. | $516.40 | 2019-2022 | |
| Ocular Therapeutix, INC. | $476.63 | 2020-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $389.81 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $293.14 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $292.14 | 2019-2021 | |
| Dompe US, INC. | $122.14 | 2022-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $104.65 | 2021-2023 | Flarex |
| Optos, INC. | $84.77 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $82.92 | 2022-2025 | Clearpath, Via360, Streamline |
| Rayner Intraocular Lenses Limited | $74.78 | 2022-2024 | Rayone Emv, Rayone Aspheric, Omidria |
| Amgen INC. | $67.01 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $63.47 | 2019-2024 | Lipiflow System Activator II (Disposable |
| Johnson & Johnson Vision Care, INC. | $44.55 | 2019 | |
| Rxsight INC | $41.83 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Shire North American Group INC | $40.62 | 2019 | |
| Sight Sciences, INC. | $35.59 | 2022 | |
| Apellis Pharmaceuticals, INC. | $26.78 | 2022 | |
| Thea Pharma INC. | $24.81 | 2023 | Iyuzeh |
| Horizon Therapeutics Plc | $20.42 | 2022 | |
| Omeros Corporation | $18.65 | 2020 | |
| Lkc Technologies, INC. | $14.65 | 2023 | |
| Carl Zeiss Meditec, INC. | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Putnoi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.